KYTX
Kyverna Therapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Kyverna Therapeutics (KYTX) Stock: Buy, Sell, or Hold?
$5.03
-0.09 (-1.76%)
âŧ
5d:
+9.11%
30d:
-11.52%
90d:
-38.43%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (95%)
Quality Score
52/100
Position
SLIGHTLY LOW
30-Day Fair Range
$5.17 â $6.09
Position: SLIGHTLY LOW
Forward P/E & Valuation
-1.6x
Next 12M consensus est.
Wall Street Target
$30.40
+504.4% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$4.50 / $5.87
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: KYTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When KYTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: KYTX is currently trading at $5.03, which is considered slightly low relative to its 30-day fair value range of $5.17 to $6.09.
Technical Outlook: Technically, KYTX is in a strong downtrend. Immediate support is located at $4.50, while resistance sits at $5.87.
Market Sentiment: KYTX scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.40 (+504.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KYTX is in a strong downtrend. Immediate support is located at $4.50, while resistance sits at $5.87.
Market Sentiment: KYTX scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.40 (+504.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.17 -
$6.09
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
Trading Range & Key Levels
30-Day Trading Range
$5.17 -
$6.09
Current vs Trading Range
SLIGHTLY LOW
Support Level
$4.50
Resistance Level
$5.87
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 504.4% below Wall St target ($30.40)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.59
Wall Street Target
$30.40
(+504.4%)
Share KYTX Analysis
Share this live KYTX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (KYTX)
Bullish
3 Retail Mentions
Reddit / WSB Comments
2
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 13, 2026
Daily AI digest
AI Retail Discussion Summary:
Kyverna Therapeutics announced the completion of the BLA submission for miv-cel in Stiff Person Syndrome and reported third quarter financial results, with the submission seeking priority review. The company is advancing commercial readiness for a potential U.S. launch of miv-cel, which could become the first approved therapy for SPS and the first approved CAR-T therapy in autoimmune disease.
Key Retail Themes:
BLA submission completion and priority review
Commercial readiness for potential U.S. launch of miv-cel
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 9:35 PM ET
Data refreshes hourly during market hours. Next update: 10:35 PM
Data refreshes hourly during market hours. Next update: 10:35 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 52 HOLD |
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$978 | 32 SELL |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 52 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 37 SELL |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 42 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive KYTX Research Pages
